prescriber.co.uk ■ NEW PRODUCTS N ICE recommends HRT for up to five years to relieve vasomotor symptoms associated with the menopause; it should also be considered for alleviating associated low mood. 1 A combined oestrogen/progestogen formulation is recommended for women with a uterus. However, combined HRT may increase the risk of breast cancer and stroke and may not protect against cardiovascular disease; trans dermal administration is preferred for women at risk of venous thromboembolism.
There are currently over 20 oral combined HRT preparations available for sequential or continuous use; most contain estradiol but two (Premique, Prempak-C) contain conjugated oestrogens in combination with a progestogen. Duavive combines conjugated oestrogens with the selective oestrogen-receptor modulator (SERM) bazedoxifene.
Properties
Duavive is a modified-release combined therapy containing conjugated oestrogens 0.45mg and bazedoxifene 20mg, taken as a single oral tablet once daily. Duavive is licensed for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestogen-containing therapy is not appropriate.
Bazedoxifene has oestrogen agonist activity in bone and antagonist activity in breast and uterine tissues. The rationale for this combination is that bazedoxifene should inhibit the proliferative effects of conjugated oestrogens on the endometrium and prevent stimulatory effects in breast tissue. In one 12-month trial, the incidence of endometrial hyperplasia and bleeding with Duavive was similar to that observed with placebo and it was not associated with breast tenderness. 2 There is little clinical experience of Duavive in women aged over 65 years, it is not recommended for women with renal impairment and it is contraindicated in those with hepatic impairment. Other prescribing cautions and contraindications are similar to those of other HRT preparations. The metabolism of bazedoxifene may be increased by rifampicin, phenobarbital, carbamazepine and phenytoin, potentially leading to decreased concentrations of bazedoxifene and increased risk of endometrial hyperplasia.
Duavive should only be used to treat symptoms that impair quality of life 
Clinical trials
Two phase 3 trials provide the key data for the efficacy of Duavive (conjugated oestrogens 0.45mg/bazedoxifene 20mg) for vasomotor symptoms (SMART-2) 3 and vulvovaginal atrophy (SMART-3). 4 Both also included a treatment arm with a higher dose of conjugated oestrogens (conjugated oestrogens 0.625mg/bazedoxifene 20mg), which was not subsequently licensed.
SMART-2 included healthy postmenopausal women with an intact uterus aged 40-65 years, who were seeking treatment for hot flushes and reporting at least seven moderate to severe hot flushes per day (baseline about 10 per day) or 50 per week. Participants were randomised to receive placebo (n=63) or treatment with Duavive (n=127) for 12 weeks. The primary endpoints were the change in frequency and severity of hot flushes.
Duavive significantly reduced the mean daily number of moderate to severe hot flushes at four weeks compared with placebo (by about six vs three; p<0.001) and 12 weeks (by about eight vs five; p<0.001) (see Table 1 ) and also reduced their average daily severity. The proportion of patients with ≥75 per cent reduction in number of hot flushes at week 12 was 67 per cent with Duavive (odds ratio vs placebo 5.23; CI 95% 2.57-10.64). 5 The European Medicines Agency (EMA) concluded that Duavive relieved vasomotor symptoms less effectively than a combination of conjugated oestrogens and medroxyprogesterone acetate, based on secondary endpoints from other studies and an historical comparison. 5 Regulatory approval for Duavive was therefore limited to circumstances when a progestogen is not appropriate. There appears to have been no trial specifically evaluating efficacy in such a population.
SMART-3 randomised healthy women aged 40-65 years with confirmed vulvovaginal atrophy who reported at least one moderate or severe vulvar or vaginal symptom to receive placebo (n=105), Duavive (n=219) or bazedoxifene 20mg daily alone (n=110). The co-primary endpoints for were vaginal maturation (increase in superficial cells, decrease in parabasal cells), lowering of vaginal pH and improvement in the most bothersome symptom. At week 12, Duavive improved signs of vaginal maturation significantly more than bazedoxifene alone or placebo but did not improve vaginal pH or the most bothersome symptom compared with placebo.
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Adverse events
The overall frequency of adverse events associated with Duavive reported in clinical trials was similar to that with placebo. 5 The most frequent adverse effects included headache, muscle and joint pain, and gastrointestinal symptoms. Approximately 8-10 per cent of women discontinued treatment due to adverse events in studies lasting up to two years in both Duavive and placebo groups. 5 There are insufficient data to determine the long-term risks of venous thromboembolism, cerebrovascular and cardiovascular disease, and cancer.
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